Indirect-Acting Cholinergic Agonists: Pharmacokinetics

Indirect-acting cholinergic agonists inhibit acetylcholinesterase enzymes, preventing the breakdown of acetylcholine (ACh) in the body. By blocking ACh hydrolysis, these agents allow acetylcholine to accumulate at cholinergic synapses, thereby enhancing cholinergic neurotransmission. This mechanism differs from direct agonists, which bind receptors directly.

Agents with quaternary nitrogen are highly polar molecules, which limits their ability to cross cell membranes and be absorbed through the gastrointestinal tract. This poor oral bioavailability requires higher effective oral doses compared to equivalent parenteral doses. Their polarity also restricts distribution to the central nervous system.

Tertiary amine agents like physostigmine are less polar than quaternary compounds, allowing excellent oral absorption and penetration across the blood-brain barrier and eye tissues. This property makes them ideal for topical ophthalmic use as eye drops and enables systemic distribution throughout the body.

Organophosphates are highly lipid-soluble compounds that are rapidly absorbed through all routes, including mucous membranes, skin, and lungs. They readily distribute throughout the body and cross the blood-brain barrier, making them particularly dangerous. They are metabolized by esterases in the liver, plasma, and skeletal muscles.

Duration depends on the agent's chemical structure and stability. Short-acting agents like edrophonium contain simple alcohol groups and are rapidly eliminated renally, lasting ten to twenty minutes. Intermediate-acting agents like neostigmine contain carbamate groups that are slowly hydrolyzed, producing effects lasting twenty minutes to six hours.

These agents are metabolized by cholinesterase enzymes located in the liver, plasma, and skeletal muscles. The resulting metabolites are primarily excreted unchanged through the kidneys via renal elimination. Organophosphates can gradually age to become resistant to hydrolysis, leading to prolonged effects and potential toxicity.

Lipid solubility determines an agent's ability to cross biological membranes and penetrate tissues. Highly lipid-soluble agents like organophosphates readily distribute throughout the body and cross the blood-brain barrier, causing systemic and central nervous system effects. Low lipid solubility restricts distribution, limiting side effects.